Buscar
Mostrando ítems 21-26 de 26
HFA of the ESC Position Paper on the Management of LVAD-Supported Patients for the Non-LVAD Specialist Healthcare Provider Part 3: At the Hospital and Discharge
(Wiley, 2021-09-28)
[Abstract] The growing population of left ventricular assist device (LVAD)-supported patients increases the probability of an LVAD- supported patient hospitalized in the internal or surgical wards with certain expected ...
Heart Failure Association of the European Society of Cardiology Position Paper on the Management of Left Ventricular Assist Device-Supported Patients for the Non-left Ventricular Assist Device Specialist Healthcare Provider: Part 2: At the Emergency Department
(Wiley, 2021-09-14)
[Abstract] The improvement in left ventricular assist device (LVAD) technology and scarcity of donor hearts have increased dramatically the population of the LVAD-supported patients and the probability of those patients ...
HFA of the ESC Position Paper on the Management of LVAD Supported Patients for the non LVAD Specialist Healthcare Provider Part 1: Introduction and at the Non-hospital Settings in the Community
(Wiley, 2021-09-14)
[Abstract] The accepted use of left ventricular assist device (LVAD) technology as a good alternative for the treatment of patients with advanced heart failure together with the improved survival of the LVAD-supported ...
Guidance on the Management of Left Ventricular Assist Device (LVAD) Supported Patients for the Non-LVAD Specialist Healthcare Provider: Executive Summary
(Wiley, 2021-08-18)
[Abstract] The accepted use of left ventricular assist device (LVAD) technology as a good alternative for the treatment of patients with advanced heart failure together with the improved survival of patients on the device ...
Unravelling the Interplay Between Hyperkalaemia, Renin–Angiotensin–Aldosterone Inhibitor Use and Clinical Outcomes. Data From 9222 Chronic Heart Failure Patients of the ESC‐HFA‐EORP Heart Failure Long‐Term Registry
(Willey Online Library, 2020-04-03)
[Abstract]
Aims.
We assessed the interplay between hyperkalaemia (HK) and renin–angiotensin–aldosterone system inhibitor (RAASi) use, dose and discontinuation, and their association with all‐cause or cardiovascular death ...
Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world
(Wiley, 2019-05-27)
[Abstract] Aims: To assess the proportion of patients with heart failure and reduced ejection fraction (HFrEF) who are eligible for sacubitril/valsartan (LCZ696) based on the European Medicines Agency/Food and Drug ...